Regenerative medicine specialist L&C Bio Co., Ltd. (290650, CEO Hwancheol Lee)'s knee cartilage osteoarthritis treatment, 'MegaCarti,' has received approval from four clinical trial institutions, allowing the clinical trials to officially commence.
After receiving approval for the clinical trial plan (IND) from the Ministry of Food and Drug Safety on December 27, 2019, the four hospitals conducting the clinical trials (Yonsei University Severance Hospital, Gangnam Severance Hospital, Korea University Anam Hospital, National Health Insurance Service Ilsan Hospital) proceeded with the IRB (Institutional Review Board) approval process, which was finally completed on March 20.
This clinical trial will be conducted at the four hospitals, involving a total of 90 patients with knee joint cartilage damage (degenerative arthritis with ICRS grade 3 to 4). MegaCarti will be implanted and patients will be followed up for one year to evaluate efficacy and safety.
Hot Picks Today
!["Don't Use Chinese-Made Products": One U.S. Warning Triggers a 5 Trillion Won Jackpot for Korean Batteries [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2025121709393659037_1765931975.jpg)
"Don't Use Chinese-Made Products": One U.S. Warning Triggers a 5 Trillion Won Jackpot for Korean Batteries [Weekend Money]
- "Dividend Payouts of 40 Million Won Before Their First Birthday"...'Baby Shareholders' Put Ordinary Workers at a Disadvantage
- Gold-Plated Door Handles and All... The World’s Only Car Sets Cadillac’s All-Time Record at 1.8 Billion Won
- Non-Resident Single Homeowner with 4.3 Billion Won Property to Pay 4.29 Million Won More in Real Estate Tax Next Year
- Order Volume Surges by 9,000%...How Generation Z in China Finds Fulfillment With Just 20,000 KRW [China.zip]
A representative from L&C Bio Co., Ltd. stated, “With 3.87 million patients suffering from degenerative arthritis in Korea, we expect the clinical recruitment to be completed soon. Compared to existing treatments, MegaCarti offers faster pain relief and price competitiveness, which we believe will greatly benefit patients struggling with degenerative arthritis.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
